Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, Ferrero S. Genuardi E, et al. Among authors: saraci e. Hematol Oncol. 2021 Aug;39(3):293-303. doi: 10.1002/hon.2864. Epub 2021 Mar 31. Hematol Oncol. 2021. PMID: 33742718 Free PMC article. Clinical Trial.
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Drandi D, et al. Among authors: saraci e. J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28. J Mol Diagn. 2015. PMID: 26319783 Free article.
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P. Oliva S, et al. Among authors: saraci e. Oncotarget. 2017 Jan 24;8(4):5924-5935. doi: 10.18632/oncotarget.12641. Oncotarget. 2017. PMID: 27779105 Free PMC article.
Relevance of sample preparation for flow cytometry.
Muccio VE, Saraci E, Gilestro M, Oddolo D, Ruggeri M, Caltagirone S, Bruno B, Boccadoro M, Omedè P. Muccio VE, et al. Among authors: saraci e. Int J Lab Hematol. 2018 Apr;40(2):152-158. doi: 10.1111/ijlh.12755. Epub 2017 Oct 6. Int J Lab Hematol. 2018. PMID: 28984084 Free article.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Gambella M, et al. Among authors: saraci e. Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18. Cancer. 2019. PMID: 30561775 Free article.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, D'Agostino M, Gilestro M, Mina R, Saraci E, Margiotta Casaluci G, Genuardi E, Bringhen S, Boccadoro M, Omedé P. Oliva S, et al. Among authors: saraci e. Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 Jan 3. Ann Hematol. 2021. PMID: 33392702
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Oliva S, Genuardi E, Paris L, D'Agostino M, Rogers J, Rota-Scalabrini D, Jacob AP, Patriarca F, Luppi M, Bertazzoni P, Velluti C, Capra A, Saraci E, Rossi M, Allegra A, Mina R, Gentile M, Kirsch IR, Belotti A, Cavo M, Bruno B, Musto P, Boccadoro M, Zamagni E, Gay F. Oliva S, et al. Among authors: saraci e. EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396800 Free PMC article.
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.
Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omedé P, Riganti C, Palumbo A, Boccadoro M, Massaia M. Castella B, et al. Among authors: saraci e. Oncoimmunology. 2015 May 26;4(11):e1047580. doi: 10.1080/2162402X.2015.1047580. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451323 Free PMC article.
17 results